Vikran Engineering, formerly known as Vikran Engineering & Exim Private Limited is an Engineering, Procurement, and Construction (EPC) company. The company is launching its ₹772 crore Initial Public Offer (IPO) on August 26, 2025 for public subscription. The bidding window for the Vikran Engineering IPO will be open till August 29, 2025 and the allotment process is expected to be finalised on September 1, 2025.
The shares of Vikran Engineering Ltd will be listed on both the BSE and NSE websites with a tentative listing date fixed as September 3, 2025.
Vikran Engineering IPO is a book build issue of ₹772.00 crores. The issue is a combination of fresh issue of 7.43 crore shares of face value of ₹1 each aggregating to ₹721.00 crores and offer for sale of 0.53 crore shares of face value of ₹1 each aggregating to ₹51.00 crores.
The IPO price band is set at ₹92 - ₹97 per share. The lot size for an application is 148. And the minimum investment required by an retail investor is ₹13,616 (148 shares).
Pantomath Capital Advisors Pvt. Ltd. is the book running lead manager and Bigshare Services Pvt. Ltd. is the registrar of the issue.
The company will utilise the net proceeds from the issue towards the following purposes:
Check out newly Listed IPOs on BSE and NSE.
Vikran Engineering Limited, established in 2008, is a prominent EPC (Engineering, Procurement & Construction) firm based in Mumbai. The company provides end-to-end turnkey solutions including conceptualization, design, supply, installation, testing, and commissioning. It primarily serves the energy, water, railway, and now expanding into solar infrastructure sectors.
In FY25, Vikran reported revenues of ₹916 crore, up from ₹786 crore in FY24, with PAT rising to ₹78 crore. Net worth expanded to ₹468 crore, while the debt/equity ratio improved to 0.58, reflecting financial strength and stability.
Explore other Upcoming IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.